BEDMINSTER, NJ, January 12, 2023 (GLOBE NEWSWIRE) — Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today announced a strategic collaboration with National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to expanding access to complex medicines. The parties have entered into a Material Transfer and Evaluation Agreement focused on exploring the potential for oral delivery of identified nucleic acids. The parties will closely collaborate on a comprehensive research program including design, formulation, and optimization in vitro And live testing of these nucleic acid formats in conjunction with Matinas proprietary LNC platform. Terms of the partnership were not otherwise disclosed.
“Our mission is dedicated to unlocking and delivering the full clinical potential of therapies that require intracellular delivery,” he said Jerome D. Jabbour, CEO and co-founder of Matinas. “We are thrilled to partner with this world-class organization to further demonstrate the capabilities of our LNC platform. We view Resilience as an ideal platform partner and are excited to partner with them in support of their mission to enable scientists to deliver their therapies quickly, safely and at scale, so patients around the world can have access the medications they need. Importantly, the nature of our collaboration and relationship with Resilience is distinct and different from our ongoing work with BioNTech, which allows us to simultaneously pursue multiple potential applications for our LNC platform in the nucleic acid space.
Matinas’ LNC platform delivery technology offers the potential for next-generation intracellular drug delivery beyond lipid nanoparticles and viral vectors with potential advantages in a broad range of therapeutics, including oral bioavailability. The core component of the LNC technology facilitates preferential cellular uptake by certain phagocytes and cells allowing for targeting and extrahepatic delivery with no observed evidence of immunogenicity or cytotoxicity.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The company is developing its internal portfolio of products and is collaborating with leading pharmaceutical companies to develop new formulations that capitalize on the unique features of the LNC platform.
Preclinical and clinical data have demonstrated that this new technology can provide solutions to many of the challenges of achieving safe and effective intracellular delivery, both for small molecules and for larger, more complex molecules, such as mRNAs, DNA plasmids, antisense oligonucleotides, and vaccines . The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages both over to lipid nanoparticles and to viral vectors.
For more information please visit www.matinasbiopharma.com.
Resilience is a technology-focused biomanufacturing company dedicated to expanding access to complex medicines. Founded in 2020, the company is building a sustainable network of end-to-end high-tech manufacturing solutions to ensure that today’s and tomorrow’s treatments can be performed quickly, safely and at scale. Resilience seeks to free up its partners to focus on discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
Matinas Forward-looking statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business, our strategy and plans, our partnerships with Resilience and BioNTech SE, the potential of our platform LNC technology and future development of its product candidates, the Company’s ability to identify and pursue development, licensing, and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain regulatory approval required and other statements that are forward-looking in nature, relying on or relating to future events or conditions. All statements other than statements of historical fact are statements that may be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “may,” “believes,” “estimates,” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including additional capital that will be required to complete clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical trials; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations affecting the Company’s products; and the other factors listed under “Risk Factors” in our SEC filings, including Forms 10-K, 10-Q, and 8-K. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after today’s date or to reflect the occurrence of unanticipated events. Matinas BioPharma product candidates are all under development and are not available for sale or use.
Source: Matinas BioPharma Holdings, Inc.